Abstract
Acute limb ischemia (ALI) occurs at a rate of 1.3% per year in patients with symptomatic peripheral arterial disease (PAD) without atrial fibrillation. Vorapaxar reduces ALI in patients with symptomatic PAD including PAD resulting from graft thrombosis and in-situ thrombosis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have